A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

This study has been completed.

Study NCT00220194 Information provided by San Bernardino Urological Associates Medical Group Inc

First Received: September 17, 2005 Last Updated: October 19, 2005 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	June 2005
Estimated Primary Completion Date:	No date given